Rivastigmine is a cholinesterase inhibitor commonly used in the treatment of mild to moderate dementia associated with Alzheimer’s and Parkinson’s diseases. It enhances cognitive function by inhibiting the breakdown of acetylcholine, a key neurotransmitter involved in memory and learning. Maintaining the pharmaceutical purity of Rivastigmine is essential for ensuring its therapeutic effectiveness, minimizing adverse effects, and meeting regulatory standards. Impurity profiling is crucial to identify and control any unwanted substances that may form during its synthesis, storage, or degradation. Here are some of its known impurities listed below.
Showing 1 - 1 of 1 products
